Alkaline water has gained popularity as a wellness product, with claims suggesting it may support liver health and help with conditions such as fatty liver disease. Fatty liver disease, or hepatic steatosis, affects a substantial proportion of UK adults and is strongly linked to metabolic factors including obesity, type 2 diabetes, and poor dietary habits. Whilst staying well-hydrated is important for overall health, there is currently no clinical evidence that alkaline water can prevent, treat, or reverse fatty liver disease. This article examines the science behind alkaline water, explores evidence-based treatments for fatty liver, and clarifies what the research actually shows about hydration and liver health.

What Is Fatty Liver Disease and How Does It Develop?

Fatty liver disease, medically termed hepatic steatosis, is defined as fat accumulation in more than 5% of hepatocytes (liver cells), or a hepatic fat fraction exceeding 5% on imaging such as MRI. This condition has become increasingly prevalent in the UK, affecting a substantial proportion of adults. The liver normally contains small amounts of fat, but when this accumulation becomes excessive, it can impair liver function and potentially progress to more serious conditions.

There are two primary types of fatty liver disease: non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ARLD). NAFLD develops in individuals who consume little to no alcohol (typically below 14 units per week for women and 21 units per week for men) and is strongly associated with metabolic factors. The condition exists on a spectrum, ranging from simple steatosis (fat accumulation alone) to non-alcoholic steatohepatitis (NASH), where inflammation and liver cell damage occur alongside fat deposition. It is worth noting that NAFLD is increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD) in newer literature, though UK patient resources and guidelines commonly continue to use the term NAFLD.

The pathophysiology of NAFLD involves complex metabolic dysfunction. Key risk factors include:

• Type 2 diabetes and insulin resistance

• Obesity, particularly central adiposity

• Dyslipidaemia (abnormal cholesterol levels)

• Metabolic syndrome

• Sedentary lifestyle and poor dietary habits

When the body becomes resistant to insulin, fat metabolism becomes dysregulated, leading to increased fat delivery to the liver and reduced fat breakdown. The liver attempts to process this excess fat, but over time, the accumulation triggers oxidative stress and inflammatory pathways. Many individuals with fatty liver disease remain asymptomatic in early stages, with the condition often discovered incidentally through blood tests showing elevated liver enzymes or during imaging for unrelated concerns. Early detection and lifestyle modification remain crucial for preventing disease progression, as recommended by NICE guidance (NG49) and supported by the British Liver Trust and NHS patient resources.

Understanding Alkaline Water: pH Levels and Health Claims

Alkaline water refers to water with a pH level above 7.0, typically ranging from 8.0 to 9.5, compared to regular drinking water which usually has a neutral pH of approximately 7.0. This elevated pH can occur naturally through contact with mineral-rich rocks or be created artificially through ionisation processes or the addition of alkaline minerals such as calcium, magnesium, and potassium.

Proponents of alkaline water claim it can neutralise acid in the body, improve hydration, boost metabolism, and provide various health benefits including supporting liver function. The underlying theory suggests that modern diets create excess acidity in the body, and consuming alkaline water can help restore pH balance. However, it is important to understand that the human body maintains tightly regulated pH levels in different compartments through sophisticated buffering systems, primarily involving the kidneys and lungs. Systemic pH is not altered by the pH of drinking water.

Common health claims associated with alkaline water include:

• Enhanced detoxification and liver support

• Improved hydration at the cellular level

• Antioxidant properties (often conflated with hydrogen-rich water, which is a separate product)

• Reduced acid reflux symptoms (based on limited, small-scale studies)

• Better nutrient absorption

The UK drinking water supply is regulated by the Drinking Water Inspectorate under the Water Supply (Water Quality) Regulations to maintain a pH between 6.5 and 9.5. Whilst alkaline water is generally considered safe for consumption, the scientific evidence supporting many of the health claims remains limited. The stomach naturally produces hydrochloric acid with a pH of approximately 1.5 to 3.5, which quickly neutralises any alkaline substances consumed. Any transient pH changes are rapidly buffered by the body's homeostatic mechanisms. This physiological reality raises questions about whether drinking alkaline water can significantly alter systemic pH levels or provide the purported health benefits, particularly regarding specific organ function such as liver health.

Can Alkaline Water Help with Fatty Liver Disease?

Currently, there is no clinical evidence demonstrating that alkaline water can prevent, treat, or reverse fatty liver disease. Alkaline water is not a licensed medicine or medical device for liver disease and is not recommended by NICE for the management of NAFLD or NASH. Whilst alkaline water has gained popularity in wellness circles, high-quality clinical trials and peer-reviewed research specifically examining its effects on hepatic steatosis are absent from the medical literature. The mechanisms by which alkaline water might theoretically benefit liver health have not been established through rigorous scientific investigation.

Some proponents suggest that alkaline water's purported antioxidant properties could reduce oxidative stress in the liver, a key factor in NAFLD progression. However, these claims lack substantiation from well-designed clinical trials. The liver possesses its own sophisticated antioxidant systems, including glutathione and various enzymatic pathways, which are far more significant in managing oxidative stress than any potential effects from drinking water with altered pH.

The body's pH regulation is primarily controlled by the kidneys and respiratory system, which maintain blood pH within a narrow range of 7.35 to 7.45 regardless of dietary intake. When alkaline water is consumed, it passes through the highly acidic stomach environment before absorption, which neutralises much of its alkalinity. Key considerations include:

• NICE guidance (NG49 and QS82) does not recommend alkaline water for liver disease

• Alkaline water is not a licensed medicine or medical device under MHRA regulation

• No UK guidelines or high-quality clinical trials support alkaline water for NAFLD or NASH

Patients with fatty liver disease should be cautious about unproven remedies and focus on evidence-based interventions supported by the NHS, NICE, and the British Liver Trust. Whilst staying well-hydrated is important for overall health, there is no scientific basis to suggest that the pH of drinking water influences liver fat accumulation or inflammation. Individuals concerned about liver health should consult healthcare professionals rather than relying on alternative water products as treatment strategies.

Evidence-Based Treatments for Fatty Liver Disease

The cornerstone of fatty liver disease management, as recommended by NICE guidelines (NG49), centres on lifestyle modification rather than pharmacological intervention for most patients. Weight loss remains the most effective evidence-based treatment, with studies demonstrating that losing 7–10% of body weight can significantly reduce liver fat, inflammation, and even fibrosis in patients with NASH.

Dietary interventions form a critical component of treatment. The Mediterranean diet, characterised by high consumption of vegetables, fruits, whole grains, legumes, nuts, and olive oil, with moderate fish intake and limited red meat, has shown particular promise in reducing hepatic steatosis. Patients should aim to reduce intake of refined carbohydrates, added sugars (particularly fructose), and saturated fats. Avoiding sugar-sweetened beverages is especially important, as these contribute significantly to liver fat accumulation.

Physical activity provides benefits independent of weight loss. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity weekly, combined with strengthening activities on two or more days. Both aerobic exercise and resistance training have been shown to reduce liver fat content, even without significant weight reduction. The mechanisms include improved insulin sensitivity, enhanced fat oxidation, and reduced systemic inflammation.

For patients with concurrent conditions, managing underlying metabolic factors is essential:

• Optimising glycaemic control in diabetes (GLP-1 receptor agonists and pioglitazone, when used for their primary indications under specialist care, may improve liver markers)

• Treating dyslipidaemia with statins as indicated for cardiovascular risk per NICE guidance (NG238); statins are not contraindicated in NAFLD. Check baseline liver function tests (LFTs) and monitor as per guidance; discontinue only if clinically indicated, such as persistent elevations more than three times the upper limit of normal or other clinical concern

• Managing hypertension

• Addressing obstructive sleep apnoea if present

Bariatric surgery may be considered for eligible patients with obesity in accordance with NICE obesity guidance, and can lead to significant improvements in liver disease. Currently, no medications are specifically licensed in the UK for treating NAFLD or NASH, though several agents are under investigation in clinical trials. Vitamin E has shown some benefit in non-diabetic NASH patients in research settings, but routine supplementation is not recommended without specialist guidance. Patients with advanced fibrosis or cirrhosis require specialist hepatology input and may need surveillance for complications including hepatocellular carcinoma (HCC). For those with cirrhosis, ultrasound with or without alpha-fetoprotein (AFP) should be performed every six months as per NICE cirrhosis guidance (NG50).

Hydration and Liver Health: What the Research Shows

Adequate hydration is fundamental to overall health and supports optimal liver function, though the relationship is more nuanced than simple cause-and-effect. The liver plays a crucial role in fluid balance and metabolism, and maintaining proper hydration helps the organ perform its numerous functions, including detoxification, protein synthesis, and metabolic regulation. However, it is the quantity and consistency of fluid intake rather than the specific type of water that matters most for liver health.

Observational studies have suggested associations between inadequate water intake and increased risk of NAFLD, though these relationships are complex and influenced by multiple confounding factors such as overall diet quality, physical activity levels, and consumption of sugar-sweetened beverages versus plain water. It is important to note that these are associations rather than proven causal links, and chronic dehydration has not been definitively established as a direct cause of metabolic disturbances or fatty liver disease.

The NHS recommends drinking 6–8 glasses (approximately 1.2 litres) of fluid daily, with water, lower-fat milk, and sugar-free drinks being healthy choices. For individuals with fatty liver disease, replacing caloric beverages with water is particularly beneficial. Key hydration principles for liver health include:

• Choosing water over sugar-sweetened drinks, which contribute to hepatic fat accumulation

• Maintaining consistent hydration throughout the day

• Increasing fluid intake during physical activity

• Monitoring urine colour as a practical hydration indicator (pale yellow suggests adequate hydration)

Whilst proper hydration supports liver function, there is no evidence that any particular type of water—whether alkaline, mineral-rich, or otherwise enhanced—provides superior benefits for liver health compared to regular tap water. The UK's tap water meets rigorous quality standards set by the Drinking Water Inspectorate and provides safe, effective hydration. Patients should focus on adequate fluid intake as part of a comprehensive approach to liver health, rather than seeking specific water products marketed with unsubstantiated health claims.

When to Seek Medical Advice for Fatty Liver

Many individuals with fatty liver disease remain asymptomatic, making regular health assessments important, particularly for those with risk factors. You should consult your GP if you have:

• Persistent fatigue or malaise

• Discomfort or a sensation of fullness in the upper right abdomen

• Unexplained weight loss

• Risk factors including obesity, type 2 diabetes, or metabolic syndrome

• Abnormal liver function tests detected during routine blood work

Your GP will typically arrange initial investigations including liver function tests (LFTs) measuring enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), alongside tests for viral hepatitis and other liver conditions to exclude alternative causes. Elevated liver enzymes warrant further assessment, though normal results do not exclude fatty liver disease. The ALT level, in particular, may indicate the degree of liver inflammation, though levels can fluctuate.

Non-invasive assessment of liver fibrosis is recommended by NICE (NG49 and QS82) for adults with NAFLD. The primary-care pathway includes:

• First-line fibrosis assessment using the FIB-4 score (or NAFLD Fibrosis Score). FIB-4 cut-offs are age-adjusted: for adults under 65 years, a score <1.3 suggests low risk, 1.3–3.25 is indeterminate, and >3.25 suggests high risk of advanced fibrosis. For adults aged 65 years and over, a higher low-risk threshold (e.g., <2.0) may be used.

• Second-line testing with the Enhanced Liver Fibrosis (ELF) test for those with indeterminate or high FIB-4 scores. An ELF score ≥10.51 indicates likely advanced fibrosis and warrants hepatology referral.

• Reassessment every three years for adults at low risk of advanced fibrosis, as per NICE quality standard QS82.

Imaging studies, particularly ultrasound, can detect hepatic steatosis, though they have limitations in quantifying fat content or distinguishing simple steatosis from NASH. In some cases, specialist referral for transient elastography (FibroScan) or, rarely, liver biopsy may be necessary.

Seek urgent medical attention if you develop:

• Jaundice (yellowing of skin or eyes)

• Severe abdominal pain or swelling

• Confusion or altered mental state

• Vomiting blood or passing black, tarry stools

• Signs of fluid retention or leg swelling

These symptoms may indicate advanced liver disease or complications requiring immediate assessment. Early detection and intervention can prevent progression to cirrhosis and liver failure. Regular monitoring through your GP, combined with committed lifestyle changes, offers the best outcomes for managing fatty liver disease. Patients should maintain open communication with healthcare providers and avoid unproven treatments, focusing instead on evidence-based strategies for liver health as outlined by NICE, the NHS, and the British Liver Trust.

Frequently Asked Questions